Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial

摘要: PurposeThe Suppression of Ovarian Function trial showed improved disease control for tamoxifen plus ovarian function suppression (OFS) compared with alone the cohort premenopausal patients who received prior chemotherapy. We present patient-reported outcomes.Patients and MethodsThe quality-of-life (QoL) analysis includes 1,722 2,045 hormone receptor–positive breast cancer randomly assigned to receive adjuvant treatment 5 years OFS or alone. Chemotherapy use before enrollment was optional. Patients completed a QoL form consisting global symptom indicators at baseline, every 6 months 24 months, annually during 3 6. Differences in change from baseline between two treatments were tested 6, 24, 60 mixed models repeated measures without chemotherapy overall.ResultsPatients on more affected than by hot f...